Emergent BioSolutions (NYSE:EBS) has signed an agreement with AstraZeneca (NYSE:AZN) to provide contract development and manufacturing (CDMO) services for large-scale drug substance manufacturing for AZN’s COVID-19 vaccine candidate, AZD1222.
{iframe}https://seekingalpha.com/news/3595106-emergent-bio-inks-deal-astrazeneca-for-manufacture-of-covidminus-19-vaccine{/iframe}